China Biotech Deal Volume Surged 81% as Western Pharma Doubles Down
A BIO China panel based on anonymous survey data from BD heads and senior dealmakers revealed that nearly 80%...
BIO China
Chinese Biotechs Shift From Building to Partnering as Deal Values Double
At BIO China, pharma executives and investors debated whether Chinese biotechs should pursue full integration or adopt partnership-led growth...